JPM26: AstraZeneca bids to accelerate oncology R&D with Modella AI acquisition
AstraZeneca has agreed to acquire Boston-based Modella AI as part of a strategy to speed up drug development across its…
Oncology
-
-
JPM26: Revolution Medicines in spotlight as industry gears up for dealmaking spree
Revolution Medicines has dominated the build-up to the 2026 J.P. Morgan Healthcare Conference, as media reports swirl around a potential…
-
Aktis Oncology kicks 2026 IPO cycle off with $210m target
The IPO class of 2026 is likely to receive its first incumbent, after Aktis Oncology set its sights on a…
-
Genmab shelves Phase III lung cancer candidate
Genmab has discontinued development of acasunlimab, a bispecific antibody that was in mid and late-stage trials for solid tumours, including…
-
Precision medicine approaches needed in oncology to match evolving SoC
As the standard of care (SoC) for new drugs in oncology continues to improve, trials need to be designed with…
-
USPTO grants patent to Genprex’s Reqorsa gene therapy
The US Patent and Trademark Office (USPTO) has granted a patent to Genprex for the use of its Reqorsa gene…
-
Redefining clinical trials in oncology and rare diseases across the Europe
Later this month, experts from the pharmaceutical and biotechnology industry and patient advocacy space will gather in Munich, Germany, to…
-
Johnson & Johnson to acquire Halda Therapeutics for $3.05bn
Johnson & Johnson (J&J) has signed a definitive agreement for the acquisition of Halda Therapeutics (Halda) in a $3.05bn cash…
-
General Proximity and Daiichi Sankyo link on oncology
General Proximity has entered a multi-target partnership with Daiichi Sankyo to apply the OmniTAC discovery platform to oncology programmes. Daiichi…
-
AI breakthrough promises earlier prostate cancer diagnosis
According to Cancer Research UK, prostate cancer is the most common cancer among men in the UK, representing 28% of…
